BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical PD-1xCTLA-4xVEGF trispecific antibody from China’s Huahui Health.